Literature DB >> 19625407

The size of the viral inoculum contributes to the outcome of hepatitis B virus infection.

Shinichi Asabe1, Stefan F Wieland, Pratip K Chattopadhyay, Mario Roederer, Ronald E Engle, Robert H Purcell, Francis V Chisari.   

Abstract

The impact of virus dose on the outcome of infection is poorly understood. In this study we show that, for hepatitis B virus (HBV), the size of the inoculum contributes to the kinetics of viral spread and immunological priming, which then determine the outcome of infection. Adult chimpanzees were infected with a serially diluted monoclonal HBV inoculum. Unexpectedly, despite vastly different viral kinetics, both high-dose inocula (10(10) genome equivalents [GE] per animal) and low-dose inocula (10 degrees GE per animal) primed the CD4 T-cell response after logarithmic spread was detectable, allowing infection of 100% of hepatocytes and requiring prolonged immunopathology before clearance occurred. In contrast, intermediate (10(7) and 10(4) GE) inocula primed the T-cell response before detectable logarithmic spread and were abruptly terminated with minimal immunopathology before 0.1% of hepatocytes were infected. Surprisingly, a dosage of 10(1) GE primed the T-cell response after all hepatocytes were infected and caused either prolonged or persistent infection with severe immunopathology. Finally, CD4 T-cell depletion before inoculation of a normally rapidly controlled inoculum precluded T-cell priming and caused persistent infection with minimal immunopathology. These results suggest that the relationship between the kinetics of viral spread and CD4 T-cell priming determines the outcome of HBV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19625407      PMCID: PMC2748002          DOI: 10.1128/JVI.00867-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Viral clearance without destruction of infected cells during acute HBV infection.

Authors:  L G Guidotti; R Rochford; J Chung; M Shapiro; R Purcell; F V Chisari
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

Review 2.  T cells and viral persistence: lessons from diverse infections.

Authors:  Paul Klenerman; Ann Hill
Journal:  Nat Immunol       Date:  2005-09       Impact factor: 25.606

3.  Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses.

Authors:  Simona Urbani; Barbara Amadei; Paola Fisicaro; Daniela Tola; Alessandra Orlandini; Luca Sacchelli; Cristina Mori; Gabriele Missale; Carlo Ferrari
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

Review 4.  Cooperation between CD4+ and CD8+ T cells: when, where, and how.

Authors:  Flora Castellino; Ronald N Germain
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

5.  Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.

Authors:  Lydie Trautmann; Loury Janbazian; Nicolas Chomont; Elias A Said; Sylvain Gimmig; Benoit Bessette; Mohamed-Rachid Boulassel; Eric Delwart; Homero Sepulveda; Robert S Balderas; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sekaly
Journal:  Nat Med       Date:  2006-08-20       Impact factor: 53.440

6.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.

Authors:  Cheryl L Day; Daniel E Kaufmann; Photini Kiepiela; Julia A Brown; Eshia S Moodley; Sharon Reddy; Elizabeth W Mackey; Joseph D Miller; Alasdair J Leslie; Chantal DePierres; Zenele Mncube; Jaikumar Duraiswamy; Baogong Zhu; Quentin Eichbaum; Marcus Altfeld; E John Wherry; Hoosen M Coovadia; Philip J R Goulder; Paul Klenerman; Rafi Ahmed; Gordon J Freeman; Bruce D Walker
Journal:  Nature       Date:  2006-08-20       Impact factor: 49.962

7.  PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion.

Authors:  Simona Urbani; Barbara Amadei; Daniela Tola; Marco Massari; Simona Schivazappa; Gabriele Missale; Carlo Ferrari
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

8.  Oscillating CD8(+) T cell effector functions after antigen recognition in the liver.

Authors:  Masanori Isogawa; Yoshihiro Furuichi; Francis V Chisari
Journal:  Immunity       Date:  2005-07       Impact factor: 31.745

9.  Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection.

Authors:  Tobias Boettler; Elisabeth Panther; Bertram Bengsch; Natalja Nazarova; Hans Christian Spangenberg; Hubert E Blum; Robert Thimme
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients.

Authors:  B Rehermann; K M Chang; J McHutchinson; R Kokka; M Houghton; C M Rice; F V Chisari
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more
  128 in total

Review 1.  Role of interleukin-21 in HBV infection: friend or foe?

Authors:  Yongyin Li; Libo Tang; Jinlin Hou
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

Review 2.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

3.  Limited hepatitis B virus replication space in the chronically hepatitis C virus-infected liver.

Authors:  S F Wieland; S Asabe; R E Engle; R H Purcell; F V Chisari
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

Review 4.  Innate and Adaptive Immune Regulation During Chronic Viral Infections.

Authors:  Elina I Zuniga; Monica Macal; Gavin M Lewis; James A Harker
Journal:  Annu Rev Virol       Date:  2015-09-02       Impact factor: 10.431

Review 5.  Immune responses to HCV and other hepatitis viruses.

Authors:  Su-Hyung Park; Barbara Rehermann
Journal:  Immunity       Date:  2014-01-16       Impact factor: 31.745

Review 6.  Revisiting Hepatitis B Virus: Challenges of Curative Therapies.

Authors:  Jianming Hu; Ulrike Protzer; Aleem Siddiqui
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

7.  Immune effectors required for hepatitis B virus clearance.

Authors:  Priscilla L Yang; Alana Althage; Josan Chung; Holly Maier; Stefan Wieland; Masanori Isogawa; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

8.  Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice.

Authors:  Zhihua Qi; Gaiyun Li; Hao Hu; Chunhui Yang; Xiaoming Zhang; Qibin Leng; Youhua Xie; Demin Yu; Xinxin Zhang; Yueqiu Gao; Ke Lan; Qiang Deng
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

Review 9.  Screening and diagnosis of HBV in low-income and middle-income countries.

Authors:  Jean-Pierre Allain; Ohene Opare-Sem
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-14       Impact factor: 46.802

Review 10.  Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.

Authors:  Maura Dandri; Joerg Petersen
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.